or Try an Advanced Search...

    Technical Analysis for INAB - IN8bio, Inc.

    Grade Last Price % Change Price Change
    D 0.34 4.20% 0.01
    INAB closed up 1.42 percent on Wednesday, November 20, 2024, on 10 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Up Up
    Historical INAB trend table...
    Date Alert Name Type % Chg
    Crossed Above 20 DMA Bullish 4.20%
    Hammer Candlestick Bullish 4.20%
    1,2,3 Pullback Bullish Bullish Swing Setup 4.20%
    Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 4.20%
    NR7 Range Contraction 4.20%
    NR7-2 Range Contraction 4.20%
    Narrow Range Bar Range Contraction 4.20%
    Wide Bands Range Expansion 4.20%
    Fell Below 20 DMA Bearish 5.68%
    NR7 Range Contraction 5.68%
    Older End-of-Day Signals for INAB ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakout about 1 hour ago
    Outside Day about 3 hours ago
    Down 5% about 3 hours ago
    Fell Below Previous Day's Low about 3 hours ago
    60 Minute Opening Range Breakdown about 3 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    INAB Chart by TradingView
    Basic chart:

    Profile

    IN8bio, Inc. Description

    IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. The company develops INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biotechnology Cancer Clinical Medicine Solid Tumors Treatment Of Cancer Stem Cell Transplantation Solid Tumor Cancers Acute Leukemia Regenerative Medicine Advanced Therapy

    Is INAB a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 14 INAB: Upcoming Presentations at SNO & ASH
    Nov 13 IN8bio GAAP EPS of -$0.15
    Nov 12 IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
    Nov 12 IN8bio Announces Plenary Oral Presentation at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting
    Nov 5 IN8bio Announces Upcoming Presentation at the 2024 American Society of Hematology (ASH) Annual Meeting
    Nov 4 IN8bio files secondary offering of common stock
    Oct 9 Why Saratoga Investment Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
    Oct 2 INAB: Restructuring Narrows Focus to AML
    Oct 1 IN8bio dips 9%, prices $12.4M private placement
    Oct 1 IN8bio Announces Pricing of $12.4 Million Private Placement
    See more INAB news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 2.47
    52 Week Low 0.217
    Average Volume 1,251,598
    200-Day Moving Average 0.80
    50-Day Moving Average 0.30
    20-Day Moving Average 0.32
    10-Day Moving Average 0.33
    Average True Range 0.04
    RSI (14) 50.25
    ADX 45.11
    +DI 24.86
    -DI 12.60
    Chandelier Exit (Long, 3 ATRs) 0.28
    Chandelier Exit (Short, 3 ATRs) 0.39
    Upper Bollinger Bands 0.37
    Lower Bollinger Band 0.27
    Percent B (%b) 0.53
    BandWidth 31.87
    MACD Line 0.01
    MACD Signal Line 0.01
    MACD Histogram 0.0004
    Fundamentals Value
    Market Cap 13.92 Million
    Num Shares 43.3 Million
    EPS -1.10
    Price-to-Earnings (P/E) Ratio -0.29
    Price-to-Sales 0.00
    Price-to-Book 2.97
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.35
    Resistance 3 (R3) 0.34 0.33 0.34
    Resistance 2 (R2) 0.33 0.33 0.33 0.34
    Resistance 1 (R1) 0.33 0.32 0.33 0.33 0.34
    Pivot Point 0.32 0.32 0.32 0.32 0.32
    Support 1 (S1) 0.31 0.31 0.31 0.31 0.30
    Support 2 (S2) 0.30 0.31 0.30 0.30
    Support 3 (S3) 0.29 0.30 0.30
    Support 4 (S4) 0.30